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Overnight incubation of human eosinophils (Eøs)
with the glucocorticoid hormone dexamethasone
(DEX; 0.1 mM) resulted in lower expression of the
CD11b, but not CD49d, antigen on their plasma
membrane, as assessed by ￿ ow cytometry. DEX
produced a consistent inhibitory effect (ranging
from 16% to 20%) when tested at a concentration
of 0.1 mM. Eø stimulation with 100 ng/ml eotaxin
produced an increase in CD11b (+26%), but not
CD11c, levels and concomitantly a reduction
(- 25%) on CD62L expression. The inhibition
exerted by DEX upon CD11b levels was also
evident following eotaxin upregulation, with a
degree of inhibition similar to that seen on basal
levels. These data highlight a novel mechanism of
action by which glucocorticoid hormones may be
effective in reducing Eø accumulation during
allergic in￿ ammation in man.
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Introduction
In￿ltration of eosinophils (Eøs) into sites of
allergic in￿ammation is a characteristic feature
of diseases such as asthma.1 The products of
activated Eøs have been shown to play a role in
manifesting the symptoms of asthma.2 Although
many in￿ammatory mediators (including lipid
mediators, cytokines and chemokines) are po-
tent activators of Eøs, very few act speci￿cally
on this cell type. Eotaxin, which is a member of
the CC family of chemokines, was isolated from
the bronchoalveolar lavage after allergen chal-
lenge in sensitized guinea pigs.3 It is a potent,
and more importantly speci￿c, activator of Eøs.
Activation of leukocytes by in￿ammatory
mediators results in shedding of the selectin
adhesion molecule CD62L from the cell surface
and upregulation of the b2 integrin CD11b/
CD18.4,5 This complex plays an important role
in adhesive and activation processes of Eøs6- 8
and eotaxin increases levels of the CD11b
subunit (Mac-1) on the cell surface of human
Eøs.9
Glucocorticoid hormones are used routinely
to treat allergic disorders, and indeed treatment
with natural or synthetic glucocorticoids is
effective in reducing the symptoms of these
diseases, including asthma.10 Although little is
known about their mechanism of action, it
appears that part of their anti-in￿ammatory
actions may be mediated indirectly by reducing
the number of circulating Eøs thereby attenuat-
ing Eø in￿ltration into allergic tissues.11,12 More
recently glucocorticoid hormones, in particular
dexamathasone (DEX), have been shown to
reduce adhesion molecule expression on se-
lected target cells. For example, DEX was active
on endothelial cells where levels of CD62E and
CD54 were increased with cytokines or lipo-
polysaccharide.13,14 Such an effect of DEX on
the activated endothelium could contribute to
the inhibition exerted by this drug on leukocyte
accumulation during the host in￿ammatory
response.13 Much less is known about the effect
of DEX upon adhesion molecules expressed by
circulating leukocytes. A study with bovine
neutrophils reported that administration of DEX
in vivo reduced basal expression of CD62L
and CD18 levels on this polymorphonuclear
leukocyte.15
To date, no studies have investigated an effect
of glucocorticoids on the adhesion molecules
expressed on Eø plasma membrane. In the
present study we have tested whether DEX
affected either basal or eotaxin-upregulated
CD11b levels on human Eøs.
Material and Methods
Isolation of human blood Eù s
Blood (80 ml) was obtained, out of the hay-
fever season, from individuals who suffered
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sodium citrate. After dextran sedimentation
(￿nal concentration 1.2% dextran; Pharmacia,
Uppsala, Sweden) the buffy coat was layered
onto histopaque gradients (density 1.077;
Sigma, Poole, UK). After centrifugation at
400 3 g for 25 min the leukocyte pellet was
collected and all procedures were carried out
at 48 C from this point. The remaining red
blood cells in the granulocyte pellet were
lysed hypotonically. Eøs were separated from
neutrophils by incubation with anti-CD16
MACS microbeads (Miltenyi Biotec GmbH,
Germany) at a concentration of 40 ml micro-
beads per 1 3 108 granulocytes followed by
elution of the Eøs on a CS-type MACS column
and magnetic separator (Milltenyi Biotec
GmbH, Germany). The Eøs obtained were
greater than 96% pure with contaminating
cells constituting of mononuclear cells. Cells
were either incubated overnight with DEX or
stimulated with eotaxin immediately (see be-
low).
Overnight incubation of Eù s with
DEX
Cells were resuspended at a concentration of
5 3 106 Eøs per ml in RPMI 1640 medium
containing 10% heat-inactivated fetal bovine
serum, 1% penicillin-streptomycin, 0.5% genta-
mycin and 2 mML-glutamine (all obtained from
Sigma, Poole, UK). One hundred ml of the cell
suspension was added to ￿at-bottomed 96-well
plates (in duplicate for each treatment). Either
100 ml buffer or different concentrations of DEX
(1±0.001mM ￿nal concentration; David Ball
Laboratories, Warwick, UK) was added to the
wells and the cells incubated at 378 C with 5%
CO2 in air for 18 h. After the incubation, the
cells were washed and either (i) resuspended in
phosphate buffered saline (PBS) containing
0.2%bovine serum albumin (BSA) for the meas-
urement of cell surface adhesion molecules or,
(ii) resuspended in RPM I 1640 containing 0.1%
BSA for stimulation with mediators.
Stimulation with mediators
Either fresh cells or cells which had been
incubated overnight with DEX or buffer were
incubated in a shaking water bath at 378 C for
30 min in the presence of buffer, human recom-
binant (hr) eotaxin (100 ng/ml ￿nal concentra-
tion; PeproTech EC Ltd, London, UK) or 0.1mM
￿nal concentration platelet activating factor
(PAF; C16 form, Sigma, Poole, UK). The reaction
was stopped by placing the samples on ice for
5 min. The cells were then pelleted and resus-
pended in PBS containing 0.2% BSA for the
measurement of cell surface adhesion mole-
cules.
Measurement of cell surface
adhesion molecules
The presence of CD11b, CD11c, CD62L and
CD49d (a4 subunit of the b1 heterodimer
CD49d/CD29) were measured on the cell sur-
face using FACS analysis as previously
described.16 For this purpose, the following
monoclonal antibodies (mAb) were used:
mouse-anti human CD11b (clone 44; Serotec,
Oxford, UK); mouse-anti human CD11c (clone
3.9; Serotec); mouse anti-human CD62L (clone
FMC46; Serotec), and mouse anti-human CD49d
(MAX68P; kindly gifted by Dr M. Robinson,
Celltech Therapeutics, Slough, UK). MAX68P is
a well characterized monoclonal antibody
which has been shown to bind to Chinese
hamster ovary cells transfected with CD49d
(personal communication, Dr M. Robinson,
Celltech Therapeutics). Brie￿y, cells were
placed in ￿at-bottomed 96-well plates (2.5 3
105 Eøs per well, 20 ml). Non-speci￿c binding
sites were blocked with 20 ml human IgG
(15 mg/ml) before the addition of 20 ml of the
appropriate mAb (giving a ￿nal concentration
of 10±20 mg/ml). Control wells were incubated
with similar amounts of mouse IgG (Sigma).
Plates were incubated at 48 C for 1 h prior to
washing and a further incubation with 40 ml of
FITC-conjugated sheep anti-mouse IgG antibody
(1:50 dilution of stock; Sigma, Poole, UK) for
30 min at 48 C. The plates were washed again
and FACS analysis performed using a FACScan II
analyser (Becton Dickinson, CA, USA) with air-
cooled 100 mW argon ion laser tuned to
488 nm and Consort 32 computer running Lysis
II software. The Eø population could be clearly
identi￿ed because of the side and forward
scatter characteristics (con￿rming in this way
the high degree of purity) and the value of the
mean ￿uorescence intensity (MFI) associated
with it was measured at 548 nm with a band
width of 10 nm (FL-1 channel). Results are
reported as the MFI units for each sample and
have been corrected for the control (mouse
IgG) value.
Statistics
Data are mean SEM of n experiments per-
formed in duplicate. Statistical analysis was
performed on raw data using the Student’s
paired t-test.
364 Mediators of In¯ ammation ´ Vol 6 ´ 1997
A. M. Das et al.Results
Effect of eotaxin on cell surface
adhesion molecule levels
When human Eøs were incubated with eotaxin
for 30 min, there was a signi￿cant increase
(21% ) in the levels of CD11b molecules on the
cell surface with a concomitant 32%reduction
in the CD62L levels (Fig. 1). In comparison, we
found no effect on the levels of CD11c. We also
examined the effect of another mediator, PAF ,
on the levels of CD11b and CD62L. From a
typical experiment where the basal levels of
CD11b was 220 MFI units, after eotaxin or PAF
exposure this increased to 277 (26%increase)
and 303 (38%increase), respectively. Similarly,
basal levels of CD62L was 131 MFI, and this
was reduced to 117 and 74 MFI units after
eotaxin and PAF stimulation, respectively.
Effect of DEX on basal and
stimulated CD11b levels
Next, we investigated the effect of DEX on the
levels of CD11b. For this series of experiments,
Eøs were incubated for 18 h with or without
the glucocorticoid hormone after which either
(i) cell surface CD11b levels were measured or,
(ii) a 30 min stimulation with eotaxin was
performed prior to quanti￿cation of cell surface
levels of CD11b. Incubation of Eøs overnight (in
the absence of DEX) did not affect CD11b
expression when compared to levels of the
integrin on freshly isolated Eøs. Further, over-
night incubation did not alter the extent of
eotaxin-stimulated CD11b increase when com-
pared to fresh Eøs (data not shown).
Following incubation with DEX there was a
signi￿cant reduction on basal CD11b expression
on Eø plasma membrane (Fig. 2). A similar
reduction was also measured after Eø stimula-
tion with eotaxin. The effect of DEX on basal
CD11b levels was investigated further, ￿nding a
similar inhibition at all doses tested (a typical
experiment is shown in the insert of Fig. 2). We
￿nally investigated whether this effect of DEX
was the result of a non-speci￿c suppression of
Eø genomic activity, or rather, was speci￿c for
CD11b. The data shown in Table 1 illustrates
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FIG. 1. The effect of eotaxin on Eù cell surface CD11b,
CD11c and CD62L levels. Freshly isolated Eù s were incu-
bated with either buffer (control) or 100 ng/ml hr eotaxin
for 30 min at 378 C. Cell surface levels of the adhesion
molecules were measured using FACS analysis. Data are
mean SEM of (n) experiments performed in duplicate.
P , 0.05 when compared with appropriate control.
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FIG. 2. The effect of DEX on basal or eotaxin-stimulated
CD11b levels on Eù s. Eù s were incubated for 18 h with
either buffer (control) or 0.1 mM DEX. Cell surface CD11b
levels were measured either immediately (basal) or after
the cells were incubated with either buffer or 100 ng/ml hr
eotaxin for a further 30 min at 378 C. Basal value (100%) was
347 MFI units. Data are mean SEM from three to four
experiments performed in duplicate. The insert shows a
typical dose response to DEX on basal CD11b levels.
P , 0.05 when compared with control (calculated on
original values).
Table 1. Effect of DEX on basal CD11b and CD49d levels on
human Eù s
Adhesion molecule Control DEX
(MFI units) (MFI units)
CD11b (n= 4) 347 24 287 25
CD49d (n= 5) 31 6 36 8
Eù s were incubated for 18 h with either buffer (control) or 0.1 mM
DEX after which the cell surface levels of CD11b and CD49d were
measured. Data are mean SEM of (n) experiments performed in
duplicate. P , 0.05 when compared with control values.
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CD49d expression on the plasma membrane of
Eøs.
Discussion
In the present study we have investigated the
effect of DEX on the expression of adhesion
molecules on the surface of human Eøs. We
examined the effect of DEX on basal, as well as
eotaxin-stimulated, CD11b levels. W e have
shown, to our knowledge for the ￿rst time, that
DEX is able to reduce the expression of CD11b
on human Eøs.
We used the CC chemokine eotaxin to
stimulate CD11b upregulation on Eøs. The
concentration of eotaxin used was shown to be
maximal for upregulating CD11b on Eøs in
previous studies.9,17 Different levels of CD11b
upregulation has been achieved between stud-
ies. One reason for the difference could be the
source of Eøs; a previous study used Eøs from
non-atopic donors9 whereas we have used Eøs
from atopic subjects. Therefore, the Eøs in the
present study might be desensitized to certain
mediators through exposure in vivo. It also
appears that the cells were more responsive to
PAF than eotaxin which is in contrast to
previous ￿ndings.9 Again, this may be due to
the desensitization status of the cells.
Together with cytokines and chemokines,
adhesion molecules play a pivotal role in the
process of leukocyte recruitment. Recently
adhesion molecules have been shown to be a
target (although not too sensitive) for glucocor-
ticoid hormone action.13 Whereas DEX effect
on CD62E or CD54 upregulation on endothelial
cells, ￿broblasts and epithelial cells is well
accepted, much less is known of the potential
effect of this steroid on leukocyte adhesion
molecules. Few studies have reported an ability
of glucocorticoid hormones to reduce basal
expression of selected adhesion molecules,
though some species speci￿city has also been
found. Prolonged (. 3 days) exposure to DEX
reduced basal levels of CD62L and CD18 on
bovine neutrophils;15 CD62L and CD11a, but
not CD11b, on rat neutrophils;18 and CD54, but
not CD11b, on rat monocytes.16 In man, treat-
ment with methyl prednisolone reduced upreg-
ulated, but not basal, CD11b expression on
neutrophils after cardiopulmonary bypass, with
no effect upon CD11a and CD11c.19 No studies
have addressed this question on Eøs.
In the present study DEX was found to
reduce both basal CD11b expression on Eø cell
surface, and this reduction explained the lower
levels measured after cell activation with eotax-
in. Therefore, the glucocorticoid affected the
basal level of the antigen expressed on the Eø
plasma membrane but not the cellular respon-
siveness to eotaxin. DEX effect was not due to
an alteration of Eø viability. Further, it was not
secondary to a non-speci￿c suppression of Eø
genomic activity as levels of a different integrin
(CD49d) were not modi￿ed with Eø incubation
with DEX. However, increased avidity, without
alterations in total expression, of CD49d has
been reported following exposure to chemo-
kines.20 It would therefore be of interest to
investigate whether DEX exerted an effect on
b1 avidity states.
From these initial data we cannot identify the
molecular mechanism by which DEX reduces
CD11b expression on human Eøs. It could be
the result of reduced gene transcription (which
may be the case for CD54 as its promoter
region contains glucocorticoid response ele-
ments (GRE)21 or, an effect on mRNA or protein
stability. The former hypothesis appears to be
unlikely since GRE in the promoter region of
the human CD11b gene has not been de-
scribed.22 However, an indirect mechanism of
DEX through transcription factors or on CD11b
vesicular turnover cannot be excluded.
Eø recruitment in experimental models of
allergic in￿ammation relies on CD11b function
as demonstrated in vitro on Eø transendothelial
migration,6 and in vivo on eotaxin-induced Eø
accumulation.23 Based on the data presented
here, the possibility that DEX may affect Eø
accumulation via, at least in part, an effect on
CD11b should be taken into account, especially
when long-lasting dose regimens are used. This
can be particularly true for human diseases,
where glucocorticoid hormones are given for
prolonged periods for the treatment of asth-
matic and allergic rhinitis.10
In conclusion, we believe the results from
this study are important in understanding the
anti-in￿ammatory mechanism(s) of actions ex-
erted by glucocorticoid hormones in diseases of
allergic in￿ammation.
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